More news – Page 4
-
Industry news
FDA approves its first nonprescription birth control pill
FDA approves first over-the-counter (OTC) contraceptive pill for use in the US − it is expected to become the most effective OTC birth control.
-
Industry news
Good safety profile of COVID-19 vaccines declared by ICMRA
COVID-19 vaccines show a very good safety profile in all age groups, including people with underlying medical conditions and pregnancy.
-
Video
European Parliament gives first stage approval for revised EMA fees
MEPs in Strasbourg follow the parliament’s health committee’s approval of report to revise how EMA charges.
-
Industry news
Dementia patients retain ability to learn using devices: study
Dementia sufferers given iPad-like devices retain the ability to learn new things, and collaborate: Linköping University study.
-
Industry news
FDA approves radical design of pacemaker with no leads
A novel design of pacemaker – called Aveir DR – for use on two chambers of the heart without the need for wires, has been approved by the FDA.
-
Industry news
MHRA Corporate Plan supports access for patients to innovation
The MHRA’s Corporate Plan for 2023-26 seeks to set out how it will enable access to innovative medical products while ensuring patient safety.
-
Industry news
Wellcome grants £5.7 million to combat MRSA
The Wellcome Trust’s Discovery Award has granted £5.7 million to a University of Sheffield team for research into antibiotic resistance.
-
Industry news
Wearables can spot Parkinson’s up to seven years earlier
A smartwatch has been shown to be able to identify Parkinson’s disease up to seven years before symptoms appeared shows Cardiff University study.
-
Industry news
AI brings control of gene expression to CRISPR tech
CRISPR, the precision gene-editing technology, has been combined with artificial intelligence to control gene expression.
-
Industry news
Australia moves to permit therapeutic use of psychedelics
The Therapeutic Goods Administration − Australia’s regulator − approves MDMA and psilocybin for treatment of PTSD and depression.
-
Industry news
AI-generated drug first to reach Phase II trials
Insilico Biotech’s INS018_055 – a drug generated by AI – is a treatment for a rare lung disease and the first AI drug to enter a Phase II trial.
-
Industry news
Stakeholder feedback sought on EMA draft clinical guidelines
The EMA has published draft guidance − ICH E6 (R3) − on good clinical practice for clinical trials, which is open for public consultation.
-
Industry news
Two paediatric type 2 diabetes oral drugs receive FDA approval
FDA approves Jardiance and Synjardy as treatments to improve the control of blood sugar in children aged 10 years and older, with type 2 diabetes.
-
Industry news
FDA issues guidance for clinical trials of psychedelic drugs
The FDA has released guidance to researchers on how to test psychedelic drugs; seeks the public’s input as to other potential uses.
-
Industry news
NHS to receive £21 million fund for AI diagnostics
NHS Trusts will be able to apply to a dedicated AI diagnostics fund which totals £21 million, the Secretary of State for Health and Social Care announced.
-
Industry news
Disposable vapes: FDA cracks down on illegal sales
The FDA operates a ‘red list’ mechanism which means that products listed there can be banned without physical examination.
-
Video
Change Across the Medical Device Landscape
InnoScot Health protects the interests of NHS Scotland and believes it is crucial for innovators to get the right regulatory advice.
-
Industry news
UK and Ireland VetMed product label guidance
Ireland’s HPRA and the UK’s VMD have produced interim guidance clarifying the joint labels for veterinary medicines authorised in the two countries.
-
Industry news
Umbrella EU-US VetMed MRA comes one step closer
EU and US make progress towards a mutual recognition agreement for manufacturing inspections of veterinary products.
-
Industry news
AI-enabled imaging cuts serious stroke diagnosis times
Med-Tech Innovation Conference keynote ‘fireside chat’: Dr Paul Bhogal, Royal London Hospital and Gianluca Casali, Johnson & Johnson.